Premium
CD 20‐positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab
Author(s) -
Yan Min,
Dong Zhaoming,
Zhao Frank,
Chauncey Thomas,
DeaunaLimayo Delva,
WangRodriguez Jessica,
Liu Dayu,
Wang HuanYou,
Pilz Renate
Publication year - 2014
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12286
Subject(s) - plasmablastic lymphoma , bortezomib , rituximab , lymphoma , medicine , cd38 , regimen , aggressive lymphoma , dexamethasone , oncology , multiple myeloma , immunology , cancer research , biology , stem cell , genetics , cd34
As a distinct type of aggressive mature large B ‐cell lymphoma, plasmablastic lymphoma ( PBL ) poses diagnostic and treatment challenges. PBL is distinguished from other B‐cell lymphomas by the presence of plasmacytic differentiation markers such as CD 38, CD 138, and MUM 1. Clinically, PBL s from oral and extra‐oral sites are rapidly progressive tumors with frequent relapse after treatment with standard diffuse large B ‐cell lymphoma regimens. Here, we report a near‐complete response of one patient with relapsed PBL following treatment with a non‐cytotoxic regimen containing bortezomib, rituximab, and dexamethasone.